An anti-major histocompatibility complex class I intrabody protects endothelial cells from an attack by immune mediators

Abstract

These results demonstrate that intrabody-mediated down-regulation of MHC I reduces the immunogenicity of RAEC which may provide a suitable alternative supply for the lining of vascular prostheses.

Potent inhibition of OKT3-induced T cell proliferation and suppression of CD147 cell surface expression in HeLa cells by scFv-M6-1B9

“…Because non-viral strategies demonstrate low transduction efficiency and transient transgene expression, viral transfer methods seem to have a greater potential for a successful gene transfer (Yamaoka et al, 2005;Doebis et al, 2006;Boldicke, 2007). Intrabody expression in HeLa cells using the adenoviral system was achieved in this study and resulted in decreasing of CD147 cell surface expression on these transduced cells (Fig.…”

“…This approach depends on a receptormediated system for retention of certain proteins within the endoplasmic reticulum (ER). Intrabodies could be a useful tool not only for clinical applications such as neurologic disorders (Messer and McLear, 2006;Emadi et al, 2007;Lynch et al, 2008) and cancer therapy Griffin et al, 2006;Tanaka et al, 2007) but also for functional analysis of proteins inside the cells (Wheeler et al, 2003;Boldicke et al, 2005;Doebis et al, 2006;Goenaga et al, 2007). Recently, we successfully produced soluble scFv against CD147 (scFv-M6-1B9) from its parental mAb, M6-1B9, using bacteria Escherichia coli.…”

Modulation of Graft Arteriosclerosis in a Rat Carotid Transplantation Model

“…A potential approach to prevent MHC I presentation is the intraendothelial expression of antibodies directed against MHC I. These intracellular antibodies, known as intrabodies, have the capacity to reduce cell surface MHC I on rat and human endothelial cells [15][16][17]. We recently developed a gene transfer method to express an anti-MHC I Intrabody in cultured ECs.…”